🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Predicting Breast Cancer With the BRAVE System

Recruitingn/aAges 18 Years - anyFemaleUniversité de Sherbrooke
NCT06498388 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Breast cancer predominates among cancer diagnoses in Canadian women. It accounts for around 25% of new cases and contributes to 13% of all cancer-related deaths. In 2020, almost 27,400 Canadian women were diagnosed with breast cancer and 5,000 of them died from it. Mammography is still the preferred method for screening for breast cancer. Although progress has been made over the years, mammography does have its drawbacks. These include physical discomfort for patients, exposure to X-rays and reduced effectiveness in dense breasts. The study team is therefore interested in developing a new breast cancer detection method, the BRAVE method. The BRAVE method, short for "BRA-based Visco-Elastography", uses the high contrast of elastic stiffness in malignant breast tumors to detect possible cancer cases without the need for X-rays or breast compression. The first phase, carried out on a sma

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * ≥18 years old * Able and willing to provide signed informed consent in French or English * Recent mammogram (\< 6 months) * Breast mass newly identified by palpation, mammography, sonography, or MRI and have been referred for additional imaging or evaluation. Specific inclusion Criteria: Group 1 - Normal Mammographic Breast Density (NMBD): Breast density A or B Group 2 - Elevated Mammographic Breast Density (EMBD): Breast density C or D Exclusion Criteria: * Pregnant or breast-feeding women * Breast implants or prior surgery/biopsy to breasts * Any disease or condition limiting the capacity to complete the examination process * Any previous or prescribed treatment against cancer
💊

What it tests

  • Stiffness measurement by visco-elastography
📍

Where

1 site
CIUSSS de l'Estrie - CHUS
Sherbrooke, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy